Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here, oh my. (I bet it will, at least partially) Here is the paper -- eurointervention.pcronline.com/article/a-doub… Check out this table> Congrats Rasha Al-Lamee et al

Just 8 days until we present the results of the placebo-controlled #ORBITA2 trial as late breaking science at #AHA23 in Philadelphia. Join us at 10:35 ET on Saturday 11/11/23. Rasha Al-Lamee Matthew Shun-Shin Prof Darrel Francis ☺ Mk CardioFellows Great Again American Heart Association

❤️‍🔥 The ORBITA2 team has arrived at #AHA23! Less than 24 hours till our LBCT session giving PCI the ultimate test! Saturday 11th November 2023 Location: Main Event Hall Philly time: 10:35 AM (GMT -5 Hrs) #ORBITA2 #AHA23 American Heart Association NHLI NIHR Imperial BRC

Presented at #CMR2024 & simultaneously published in European Society of Cardiology EHJ- academic.oup.com/eurheartj/adva… Our work BSCMR led by George Thornton Thomas Treibel Anvesha Singh we show that cmr myocardial Fibrosis predicts outcomes in Aortic Stenosis 10 years out! Mamas A. Mamas Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

New Stress Perfusion CMR webinar ‼️with internationally renowned experts C Bucciarelli-Ducci and Sven Plein 🧲 Follow the link to register 👇🏻 tinyurl.com/Bscmrwebinar BSCMR comms team Tamara Naneishvili Gabriella Captur BSCMR president Colin Berry SaulMyerson

Here we go again! Want to see if the coronary sinus reducer works in refractory angina? Watch Michael Foley present the results of the ORBITA-COSMIC in the main arena at #ACC this Monday #ORBITA Fiyyaz Ahmed-Jushuf Matthew Shun-Shin Shayna Chotai Christopher Rajkumar Florentina Simader

Amazing to see a brilliant friend and colleague Michael Foley present the #ORBITA-COSMIC trial of the coronary sinus reducer with simultaneous publication in The Lancet Rasha Al-Lamee NHLI Imperial NHS 💙 #ACC2024 thelancet.com/journals/lance…

ICYMI: Watch this insightful video by Drs. Rasha Al-Lamee & Christopher Rajkumar where they shed light on their #JACC paper discussing the N-of-1 trial of angina verification before #PCI. Access the full 📄 here: bit.ly/4bfHcoJ #EuroPCR #ORBITA Harlan Krumholz

In ORBITA-STAR, angina verification with an ischaemic stimulus powerfully predicted response to PCI. #EuroPCR2024 Perhaps we have been too focused on treatment when the problem always lay in the diagnosis! Published today in #JACC jacc.org/doi/10.1016/j.… Rasha Al-Lamee

The orbita group Rasha Al-Lamee Prof Darrel Francis ☺ Mk CardioFellows Great Again and co are the most innovative group in cardiology RCTs in the last 10 years. Not just brilliant, they execute and change clinical practice.

In contention for BEST study of the year thus far N of 1 trial of patient-blinded occlusion of target vessel The more angina was inducible, the more symptom relief after PCI Best 2 figures Now, how best to verify if symptoms truly are angina?

The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in JACC Journals by Florentina Simader and Christopher Rajkumar. PCI isn’t a therapy for all symptoms, it’s a therapy for angina Rasha Al-Lamee Matthew Shun-Shin

.Florentina Simader on #ORBITA-2 at #EuroPCR: 📌Poor correlation between symptoms & disease severity 📌Symptom nature is a powerful predictor of the placebo-controlled efficacy of #PCI 📌Rose angina & typical angina are excellent predictors of the placebo-controlled efficacy of PCI

Now I’m officially bursting with pride!

Should PCI be an option for first line management of stable angina symptoms? Point and counterpoint in Circ: CQO with final word from Brahmajee Nallamothu and TCTMD ahajournals.org/doi/full/10.11… Rasha Al-Lamee

KOLs boost Early Aortic Valve Intervention in Patients with Asymptomatic AS--Despite Dubious Evidence: JAMA Cardiology featured a strong editorial urging cardiologists to intervene early in patients who have aortic valve stenosis and no symptoms. I do not agree via John Mandrola, MD

ahajournals.org/doi/10.1161/CI… Highest congratulations to the authors, Dr. Signe Glargaard et al